These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38655202)

  • 1. B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.
    Jacob-Dolan C; Lifton M; Powers OC; Miller J; Hachmann NP; Vu M; Surve N; Mazurek CR; Fisher JL; Rodrigues S; Patio RC; Anand T; Le Gars M; Sadoff J; Schmidt AG; Barouch DH
    iScience; 2024 May; 27(5):109716. PubMed ID: 38655202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
    Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
    PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
    Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
    Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
    Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
    medRxiv; 2023 Mar; ():. PubMed ID: 36993404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Sadoff J; Le Gars M; Brandenburg B; Cárdenas V; Shukarev G; Vaissiere N; Heerwegh D; Truyers C; de Groot AM; Jongeneelen M; Kaszas K; Tolboom J; Scheper G; Hendriks J; Ruiz-Guiñazú J; Struyf F; Van Hoof J; Douoguih M; Schuitemaker H
    Vaccine; 2022 Jul; 40(32):4403-4411. PubMed ID: 35667914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.
    He X; Aid M; Chandrashekar A; Yu J; McMahan K; Wegmann F; Jacob-Dolan C; Maron JS; Atyeo C; Wan H; Sellers D; Liu J; Lifton M; Gardner S; Bondzie EA; Barrett J; Ahmad K; Anioke T; Yalley-Ogunro J; Muench J; Goode A; Andersen H; Lewis MG; Alter G; Schuitemaker H; Zahn R; Barouch DH
    Sci Transl Med; 2022 Mar; 14(638):eabm4996. PubMed ID: 35191769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice.
    Mahrokhian SH; Tostanoski LH; Jacob-Dolan C; Zahn RC; Wegmann F; McMahan K; Yu J; Gebre MS; Bondzie EA; Wan H; Powers O; Ye T; Barrett J; Schuitemaker H; Barouch DH
    NPJ Vaccines; 2022 Feb; 7(1):23. PubMed ID: 35197477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
    Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Roux JL; Lustig G; Madzivhandila M; Magugu SF; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    medRxiv; 2023 Nov; ():. PubMed ID: 38045321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
    Riou C; Bhiman JN; Ganga Y; Sawry S; Ayres F; Baguma R; Balla SR; Benede N; Bernstein M; Besethi AS; Cele S; Crowther C; Dhar M; Geyer S; Gill K; Grifoni A; Hermanus T; Kaldine H; Keeton RS; Kgagudi P; Khan K; Lazarus E; Le Roux J; Lustig G; Madzivhandila M; Magugu SFJ; Makhado Z; Manamela NP; Mkhize Q; Mosala P; Motlou TP; Mutavhatsindi H; Mzindle NB; Nana A; Nesamari R; Ngomti A; Nkayi AA; Nkosi TP; Omondi MA; Panchia R; Patel F; Sette A; Singh U; van Graan S; Venter EM; Walters A; Moyo-Gwete T; Richardson SI; Garrett N; Rees H; Bekker LG; Gray G; Burgers WA; Sigal A; Moore PL; Fairlie L
    PLOS Glob Public Health; 2024; 4(4):e0002703. PubMed ID: 38603677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
    Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
    Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
    Swart M; van der Lubbe J; Schmit-Tillemans S; van Huizen E; Verspuij J; Gil AI; Choi Y; Daal C; Perkasa A; de Wilde A; Claassen E; de Jong R; Wiese KE; Cornelissen L; van Es M; van Heerden M; Kourkouta E; Tahiri I; Mulders M; Vreugdenhil J; Feddes-de Boer K; Muchene L; Tolboom J; Dekking L; Juraszek J; Vellinga J; Custers J; Bos R; Schuitemaker H; Wegmann F; Roozendaal R; Kuipers H; Zahn R
    NPJ Vaccines; 2023 Mar; 8(1):40. PubMed ID: 36927774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
    Stephenson KE; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Truyers C; Atyeo C; Loos C; Chandrashekar A; McMahan K; Tostanoski LH; Yu J; Gebre MS; Jacob-Dolan C; Li Z; Patel S; Peter L; Liu J; Borducchi EN; Nkolola JP; Souza M; Tan CS; Zash R; Julg B; Nathavitharana RR; Shapiro RL; Azim AA; Alonso CD; Jaegle K; Ansel JL; Kanjilal DG; Guiney CJ; Bradshaw C; Tyler A; Makoni T; Yanosick KE; Seaman MS; Lauffenburger DA; Alter G; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H; Barouch DH
    JAMA; 2021 Apr; 325(15):1535-1544. PubMed ID: 33704352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.